165 related articles for article (PubMed ID: 12069991)
21. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
Hyafil F; Vergely C; Du Vignaud P; Grand-Perret T
Cancer Res; 1993 Oct; 53(19):4595-602. PubMed ID: 8402633
[TBL] [Abstract][Full Text] [Related]
22. Determination of amprenavir total and unbound concentrations in plasma by high-performance liquid chromatography and ultrafiltration.
Barrail A; Le Tiec C; Paci-Bonaventure S; Furlan V; Vincent I; Taburet AM
Ther Drug Monit; 2006 Feb; 28(1):89-94. PubMed ID: 16418700
[TBL] [Abstract][Full Text] [Related]
23. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function.
Veronese L; Rautaureau J; Sadler BM; Gillotin C; Petite JP; Pillegand B; Delvaux M; Masliah C; Fosse S; Lou Y; Stein DS
Antimicrob Agents Chemother; 2000 Apr; 44(4):821-6. PubMed ID: 10722476
[TBL] [Abstract][Full Text] [Related]
24. The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.
Polli JW; Baughman TM; Humphreys JE; Jordan KH; Mote AL; Webster LO; Barnaby RJ; Vitulli G; Bertolotti L; Read KD; Serabjit-Singh CJ
Drug Metab Dispos; 2004 Jul; 32(7):722-6. PubMed ID: 15205387
[TBL] [Abstract][Full Text] [Related]
25. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR.
de Bruin M; Miyake K; Litman T; Robey R; Bates SE
Cancer Lett; 1999 Nov; 146(2):117-26. PubMed ID: 10656616
[TBL] [Abstract][Full Text] [Related]
26. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.
Shaik N; Giri N; Pan G; Elmquist WF
Drug Metab Dispos; 2007 Nov; 35(11):2076-85. PubMed ID: 17709369
[TBL] [Abstract][Full Text] [Related]
27. In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor.
Sadler BM; Gillotin C; Lou Y; Stein DS
Antimicrob Agents Chemother; 2001 Mar; 45(3):852-6. PubMed ID: 11181371
[TBL] [Abstract][Full Text] [Related]
28. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.
Fätkenheuer G; Römer K; Kamps R; Salzberger B; Burger D
AIDS; 2001 Nov; 15(17):2334-5. PubMed ID: 11698713
[No Abstract] [Full Text] [Related]
30. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
31. Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects.
Sadler BM; Chittick GE; Polk RE; Slain D; Kerkering TM; Studenberg SD; Lou Y; Moore KH; Woolley JL; Stein DS
J Clin Pharmacol; 2001 Apr; 41(4):386-96. PubMed ID: 11304895
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing.
Sadler BM; Gillotin C; Lou Y; Stein DS
Antimicrob Agents Chemother; 2001 Jan; 45(1):30-7. PubMed ID: 11120940
[TBL] [Abstract][Full Text] [Related]
33. In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells.
den Ouden D; van den Heuvel M; Schoester M; van Rens G; Sonneveld P
Leukemia; 1996 Dec; 10(12):1930-6. PubMed ID: 8946933
[TBL] [Abstract][Full Text] [Related]
34. The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice.
Salama NN; Kelly EJ; Bui T; Ho RJ
J Pharm Sci; 2005 Jun; 94(6):1216-25. PubMed ID: 15858856
[TBL] [Abstract][Full Text] [Related]
35. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Bardelmeijer HA; Beijnen JH; Brouwer KR; Rosing H; Nooijen WJ; Schellens JH; van Tellingen O
Clin Cancer Res; 2000 Nov; 6(11):4416-21. PubMed ID: 11106262
[TBL] [Abstract][Full Text] [Related]
36. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.
Wood R; Arasteh K; Stellbrink HJ; Teofilo E; Raffi F; Pollard RB; Eron J; Yeo J; Millard J; Wire MB; Naderer OJ
Antimicrob Agents Chemother; 2004 Jan; 48(1):116-23. PubMed ID: 14693528
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein.
Starling JJ; Shepard RL; Cao J; Law KL; Norman BH; Kroin JS; Ehlhardt WJ; Baughman TM; Winter MA; Bell MG; Shih C; Gruber J; Elmquist WF; Dantzig AH
Adv Enzyme Regul; 1997; 37():335-47. PubMed ID: 9381979
[TBL] [Abstract][Full Text] [Related]
38. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
Ose A; Kusuhara H; Yamatsugu K; Kanai M; Shibasaki M; Fujita T; Yamamoto A; Sugiyama Y
Drug Metab Dispos; 2008 Feb; 36(2):427-34. PubMed ID: 18039806
[TBL] [Abstract][Full Text] [Related]
39. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver.
Booth CL; Brouwer KR; Brouwer KL
Cancer Res; 1998 Aug; 58(16):3641-8. PubMed ID: 9721873
[TBL] [Abstract][Full Text] [Related]
40. Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy.
Eke AC; Wang J; Amin K; Shapiro DE; Stek A; Smith E; Chakhtoura N; Basar M; George K; Knapp KM; João EC; Rungruengthanakit K; Capparelli E; Burchett S; Mirochnick M; Best BM;
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]